PriceTargets.com logo

Protara Therapeutics - TARA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $26.50
  • Forecasted Upside: 757.61%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$3.09 As of 05/17/2024 01:00 AM ET
▼ -0.65 (-17.38%)

This chart shows the closing price for TARA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Protara Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TARA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TARA

Analyst Price Target is $26.50
▲ +757.61% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Protara Therapeutics in the last 3 months. The average price target is $26.50, with a high forecast of $30.00 and a low forecast of $23.00. The average price target represents a 757.61% upside from the last price of $3.09.

This chart shows the closing price for TARA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Protara Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/25/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/18/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$23.00Low
4/22/2024OppenheimerBoost TargetOutperform ➝ Outperform$26.00 ➝ $30.00Low
4/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$23.00Low
3/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$23.00Low
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$23.00Low
3/9/2023HC WainwrightReiterated RatingBuy$23.00Low
8/10/2022HC WainwrightLower TargetBuy$30.00 ➝ $23.00Low
3/10/2022HC WainwrightReiterated RatingBuy$40.00Medium
11/8/2021OppenheimerBoost TargetOutperform$32.00 ➝ $34.00High
8/30/2021Bank of AmericaInitiated CoverageBuyLow
6/4/2021HC WainwrightInitiated CoverageBuy$40.00Medium
4/26/2021OppenheimerLower TargetOutperform$43.00 ➝ $32.00High
3/21/2021OppenheimerReiterated RatingBuy$43.00Medium
2/17/2021OppenheimerInitiated CoverageOutperform$43.00Low
10/19/2020CowenInitiated CoverageOutperform$50.00High
7/29/2020GuggenheimInitiated CoverageBuy$50.00High
1/22/2020LADENBURG THALM/SH SHInitiated CoverageBuy$45.00High
(Data available from 5/18/2019 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/21/2023
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/19/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/18/2024

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Protara Therapeutics logo
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.
Read More

Today's Range

Now: $3.09
Low: $2.95
High: $3.74

50 Day Range

MA: $3.38
Low: $2.64
High: $4.15

52 Week Range

Now: $3.09
Low: $1.04
High: $5.24

Volume

798,115 shs

Average Volume

465,596 shs

Market Capitalization

$63.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Protara Therapeutics?

The following sell-side analysts have issued reports on Protara Therapeutics in the last year: HC Wainwright, and Oppenheimer Holdings Inc..
View the latest analyst ratings for TARA.

What is the current price target for Protara Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Protara Therapeutics in the last year. Their average twelve-month price target is $26.50, suggesting a possible upside of 757.6%. Oppenheimer Holdings Inc. has the highest price target set, predicting TARA will reach $30.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $23.00 for Protara Therapeutics in the next year.
View the latest price targets for TARA.

What is the current consensus analyst rating for Protara Therapeutics?

Protara Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TARA will outperform the market and that investors should add to their positions of Protara Therapeutics.
View the latest ratings for TARA.

What other companies compete with Protara Therapeutics?

Other companies that are similar to Protara Therapeutics include Turnstone Biologics, Entera Bio, Atara Biotherapeutics, Ikena Oncology and Champions Oncology. Learn More about companies similar to Protara Therapeutics.

How do I contact Protara Therapeutics' investor relations team?

Protara Therapeutics' physical mailing address is 1 LITTLE WEST 12TH STREET, NEW YORK NY, 10014. The company's listed phone number is (646) 844-0337 and its investor relations email address is [email protected]. The official website for Protara Therapeutics is www.proteontherapeutics.com. Learn More about contacing Protara Therapeutics investor relations.